RxDoctor Payments Data

Jaspreet Sandhu, MD

Urology · New York, NYNPI 1508843988

Payments from drug & device makers

$3,550in general payments, 2019–2025

Across 40 payments — averaging $88.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Boston Scientific$1K
  • Profound Medical Corp.$172
  • Pfizer$150
  • Axonics, Inc.$145
  • Olympus America Inc.$143
  • plus $364 from 4 others

What the payments were for

  • Food & beverage$3,46698%
  • Education$842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation14$1,409
Boston Scientific14$1,167
Profound Medical Corp.1$172
Pfizer1$150
Axonics, Inc.1$145
Olympus America Inc.1$143
Innovation Technologies Inc1$127
Ferring Pharmaceuticals Inc.2$97
Rochester Medical Corporation2$84
Coloplast3$56

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,550 in reported general payments places this provider in the 55th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$193,347
Medicare patients
883
Services billed
1,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron288$212,850
GemtesaVibegron71$69,912
Tamsulosin Hcl503$10,564
Tadalafil42$6,394
Silodosin33$4,208
Finasteride234$3,669
Solifenacin Succinate59$2,652
Estradiol16$1,896
Alfuzosin Hcl ErAlfuzosin Hcl66$1,669
Dutasteride41$1,314
Tolterodine Tartrate ErTolterodine Tartrate24$1,287
Oxybutynin Chloride ErOxybutynin Chloride40$970
Risedronate Sodium11$658
NitrofurantoinNitrofurantoin Macrocrystal12$534
Terazosin Hcl13$420

Paid to pharmacies, not to this prescriber.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →